Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Since their introduction in clinical practice in the 1950's, Sulfonylureas (SUs) have remained the main-stay of pharmacotherapy in the management of type 2 diabetes. Despite their well-established benefits, their place in therapy is inappropriately being overshadowed by newer therapies. Many of the clinical issues associated with the use of SUs are agent-specific, and do not pertain to the class as such. Modern SUs (glimepiride, gliclazide MR) are backed by a large body of evidence, experience, and most importantly, outcome data, which supports their role in managing patients with diabetes. Person-centred care, i.e., careful choice of SU, appropriate dosage, timing of administration, and adequate patient counseling, will ensure that deserving patients are not deprived of the advantages of this well-established class of anti-diabetic agents. Considering their efficacy, safety, pleiotropic benefits, and low cost of therapy, SUs should be considered as recommended therapy for the treatment of diabetes in South Asia. This initiative by SAFES aims to encourage rational, safe and smart prescription of SUs, and includes appropriate medication counseling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 2×
“[26] This benefit persisted for up to 10 years in patients who had attained better glycaemic control.[60] Similar results were observed from 15 well designed long term (≥72‐weeks) RCTs, including ADOPT, ADVANCE[52] and ADVANCE‐ON,[61] where treatment with SUs was not found to be associated with an increase in CVD risk…”
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962 · cited 2×
“In UKPDS and ADOPT, majority of patients treated with glibenclamide experienced a loss of effective antidiabetic response after an initial excellent response (secondary failure).[26,30,53] In contrast, data from a systemic review of three RCTs reported lowest rates of secondary failure with gliclazide (7.”
Pancreatic β Cell Dedifferentiation as a Mechanism of Diabetic β Cell Failure
Talchai, C., Xuan, S., Lin, H. V., Sussel, L., & Accili, D. (2012) · Cell · doi:10.1016/j.cell.2012.07.029 · Cited by 1,415 · cited 1×
“De‐differentiated β‐cells reverted to progenitor‐like cells expressing neurogenin3, Oct4, Nanog, and L‐Myc, consequently expressing non β‐cell hormones such as somatostatin and glucagon.[89,90] Thus β‐cell de‐differentiation may account for reduced β‐cell mass and insulin secretion in patients with T2DM.”
Cloning of the β Cell High-Affinity Sulfonylurea Receptor: a Regulator of Insulin Secretion
Aguilar-Bryan, L., Nichols, C. G., Wechsler, S. W., Clement, J. P., Boyd, A. E., González, G., Herrera-Sosa, H., Nguy, K., Bryan, J., & Nelson, D. A. (1995) · Science · doi:10.1126/science.7716547 · Cited by 1,315
A comparison of glyburide and insulin in women with gestational diabetes mellitus
Langer, O., Conway, D. L., Berkus, M. D., Xenakis, E. M.-J., & Gonzales, O. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431601 · Cited by 924 · cited 1×
“[145‐147] Studies using a single‐cotyledon placental model have found minimal trans‐placental transfer of glibenclamide; an observation that paved the way for further research on its role in the management of gestational diabetes mellitus.[148,149] However, contradicting results from other studies, together with lack…”
Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes
Hayward, R. A., Reaven, P. D., Wiitala, W. L., Bahn, G. D., Reda, D. J., Ge, L., McCarren, M., Duckworth, W. C., & Emanuele, N. V. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414266 · Cited by 668 · cited 2×
“This data provides evidence that a current multidrug glycemic treatment regimen (which includes glimepiride) can be associated with a significant reduction in major macrovascular events even among older patients who have had diabetes for many years.[62] The major outcomes of treatment with SUs in landmark trials have…”
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes
Zoungas, S., Chalmers, J., Neal, B., Billot, L., Li, Q., Hirakawa, Y., Arima, H., Monaghan, H., Joshi, R., Colagiuri, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407963 · Cited by 626 · cited 2×
“[60] Similar results were observed from 15 well designed long term (≥72‐weeks) RCTs, including ADOPT, ADVANCE[52] and ADVANCE‐ON,[61] where treatment with SUs was not found to be associated with an increase in CVD risk or mortality.”
Frequency of Severe Hypoglycemia Requiring Emergency Treatment in Type 1 and Type 2 Diabetes
Leese, G. P., Wang, J., Broomhall, J., Kelly, P., Marsden, A., Morrison, W., Frier, B. M., Morris, A. D., & For the DARTS/MEMO Collaboration (2003) · Diabetes Care · doi:10.2337/diacare.26.4.1176 · Cited by 559
Handelsman, Y., Mechanick, J. I., Blonde, L., Grunberger, G., Bloomgarden, Z. T., Bray, G. A., Dagogo-Jack, S., Davidson, J. A., Einhorn, D., Ganda, O., et al. (2011) · Endocrine Practice · doi:10.4158/ep.17.s2.1 · Cited by 513 · cited 1×
“The current consensus is developed in accordance with the American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE) protocol for standardized production of clinical practice guidelines.[34] Recommendations were graded based on clinical importance and levels of evidence as described…”
Sulfonylurea Stimulation of Insulin Secretion
Proks, P., Reimann, F., Green, N., Gribble, F., & Ashcroft, F. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s368 · Cited by 510 · cited 2×
“Individual SUs differ in their hypoglycaemic potential, mainly due to the duration and time of action, dose equivalence and affinity to SUR on β‐cells.[48] SU‐induced hypoglycaemia with or without the need of external assistance occurs in about 1 in every 100 persons per year.”
Tzoulaki, I., Molokhia, M., Curcin, V., Little, M. P., Millett, C. J., Ng, A., Hughes, R. I., Khunti, K., Wilkins, M. R., Majeed, A., et al. (2009) · BMJ · doi:10.1136/bmj.b4731 · Cited by 444
Johnson, J. A., Majumdar, S. R., Simpson, S. H., & Toth, E. L. (2002) · Diabetes Care · doi:10.2337/diacare.25.12.2244 · Cited by 421
Schramm, T. K., Gislason, G. H., Vaag, A., Rasmussen, J. N., Folke, F., Hansen, M. L., Fosbøl, E. L., Køber, L., Norgaard, M. L., Madsen, M., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr077 · Cited by 418
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-3-199802010-00001 · Cited by 385
The Role of Sulphonylureas in the Management of Type 2 Diabetes Mellitus
Rendell, M. (2004) · Drugs · doi:10.2165/00003495-200464120-00006 · Cited by 308
Cardiovascular Outcomes in Trials of Oral Diabetes Medications: A Systematic Review
Selvin, E., Bolen, S., Yeh, H.-C., Wiley, C., Wilson, L. M., Marinopoulos, S. S., Feldman, L., Vassy, J., Wilson, R., Bass, E. B., et al. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.19.2070 · Cited by 300
Schernthaner, G., Grimaldi, A., Di Mario, U., Drzewoski, J., Kempler, P., Kvapil, M., Novials, A., Rottiers, R., Rutten, G. E. H. M., & Shaw, K. M. (2004) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2004.01381.x · Cited by 271
Holstein, A., Plaschke, A., & Egberts, E. (2001) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.235 · Cited by 264 · cited 7×
“6/1000 person‐years, respectively).[46]”
InfluentialDraeger, K., Wernicke-Panten, K., Lomp, H.-J., Schüler, E., & Roßkamp, R. (1996) · Hormone and Metabolic Research · doi:10.1055/s-2007-979830 · Cited by 161
Müller, G., Hartz, D., Pünter, J., Ökonomopulos, R., & Kramer, W. (1994) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(94)90177-5 · Cited by 81
Defining a binding pocket for sulfonylureas in ATP‐sensitive potassium channels
Vila‐Carriles, W. H., Zhao, G., & Bryan, J. (2007) · The FASEB Journal · doi:10.1096/fj.06-6730hyp · Cited by 68 · cited 1×
“[42] While most SUs possess both sulfonyl and benzamido moieties [Figure 2] and interact with SUR1 and SUR2, short‐chain molecules (gliclazide), with no benzamido moiety, bind only to the sulfonyl site.”
Managing diabetes in patients with chronic liver disease
Khan, R., Foster, G. R., & Chowdhury, T. A. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.07.2574 · Cited by 34 · cited 6×
“[160] Further, alcohol induced enzyme degradation of SUs in patients with alcoholic liver disease may decrease clinical effectiveness of SUs.”
InfluentialRaptis, S., Hatziagelaki, E., Dimitriadis, G., Draeger, K., Pfeiffer, C., & Raptis, A. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1212125 · Cited by 20
Cited by
Volgman, A. S., Palaniappan, L. S., Aggarwal, N. T., Gupta, M., Khandelwal, A., Krishnan, A. V., Lichtman, J. H., Mehta, L. S., Patel, H. N., Shah, K. S., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000580 · Cited by 552
Kalra, S., Bahendeka, S., Sahay, R., Ghosh, S., Md, F., Orabi, A., Ramaiya, K., Al Shammari, S., Shrestha, D., Shaikh, K., et al. (2018) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_556_17 · Cited by 101
“[120] A systematic review and network meta-analysis evaluated the efficacy of triple therapy regimen for T2DM.”
BackgroundInfluentialSelf-citationHossain, M. A., & Pervin, R. (2018) · Nutritional and Therapeutic Interventions for Diabetes and Metabolic Syndrome · doi:10.1016/b978-0-12-812019-4.00034-9 · Cited by 47
Metadata
- Authors
- Kalra, S., Aamir, A., Raza, A., Das, A., Azad Khan, A., Shrestha, D., Qureshi, M. F., Fariduddin, M., Pathan, M. F., Jawad, F., Bhattarai, J., Tandon, N., Somasundaram, N., Katulanda, P., Sahay, R., Dhungel, S., Bajaj, S., Chowdhury, S., Ghosh, S., Madhu, S., Ahmed, T., & Bulughapitiya, U.
- Venue
- Indian Journal of Endocrinology and Metabolism
- Publisher
- Medknow
- Published
- 2015
- Volume
- 19
- Issue
- 5
- Pages
- 577
- ISSN
- 2230-8210 (ISSN-L)
- OpenAlex
- W1871508201
- Cited by
- 111
- References
- 28
- FWCI
- 8.61
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.